JP Morgan Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $38
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
JP Morgan analyst Tessa Romero initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $38.
JP Morgan analyst Tessa Romero initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $38.